What is BHVN (BHVN) stock price today?

BHVN (BHVN) is currently trading at $14.07, up 3.19% today.

What is BHVN P/E ratio?

BHVN's P/E ratio is -6.11. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is BHVN return on equity (ROE)?

BHVN's return on equity (ROE) is -333.00%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is BHVN's market cap?

BHVN has a market capitalization of $2.12B.

NYSE · Biotechnology

BHVN (BHVN) Stock

$14.07 +3.19% NYSE: BHVN Healthcare

Valuation

Metric	Value
Price	$14.07
Market Cap	$2.12B
P/E Ratio	-6.11
P/B Ratio	13.87
P/S Ratio	0.00
EPS (TTM)	$0.00
52-Week High	$18.57
52-Week Low	$7.48
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-333.00%
ROA	-83.38%
ROCE	-1432.69%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	2.21
Current Ratio	3.17

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-219.0M	$-568.0M	$-436.0M	$-885.0M	$-745.0M
Net Profit	$-214.0M	$-570.0M	$-408.0M	$-846.0M	$-739.0M
EPS	$-5.97	$-12.75	$-5.73	$-9.28	$-6.86
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$142.0M	$662.0M	$513.0M	$615.0M	$451.0M
Total Liabilities	$47.0M	$123.0M	$85.0M	$192.0M	$399.0M
Cash	$76.0M	$205.0M	$248.0M	$99.0M	$230.0M
Borrowings	$3.0M	$34.0M	$31.0M	$37.0M	$285.0M

Latest News

Bexorg Expands Leadership Team with Appointments of Bruce Car, Ph.D., as Chief Scientific Officer and Michael Fenn, Ph.D., as Chief Business Officer GlobeNewswire · Jul 13, 2026 ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership BioPharma Dive · Jul 10, 2026 Is Biohaven’s (BHVN) R&D Shake-Up Quietly Redefining Its Late-Stage Pipeline Strategy? Simply Wall St. · Jul 10, 2026 Biohaven Chief Scientific Officer Bruce Car to Transition to Chief Innovation Officer MT Newswires · Jul 9, 2026 Biohaven Announces Scientific Leadership Transitions PR Newswire · Jul 9, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-146.0M	$-298.0M	$-332.0M	$-582.0M	$-609.0M
Investing Cash Flow	$0	$-346.0M	$127.0M	$-249.0M	$300.0M
Financing Cash Flow	$138.0M	$35.0M	$-31.0M	$2.0M	$0
Net Cash Flow	$-6.0M	$166.0M	$10.0M	$-150.0M	$130.0M
Free Cash Flow	$-147.0M	$-339.0M	$-335.0M	$-587.0M	$-610.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	-48.04
EV / EBITDA	-2.69
FCF Yield	-47.11%
Quick Ratio	7.41
Interest Coverage	—
Return 1Y	6.55%
Return 3Y	-38.56%
Return 5Y	—

Ownership

Insiders Held11.08%

Institutions Held91.58%

Institutions Float Held102.99%

Institutional Holder	Shares	Report Date
Janus Henderson Group PLC	17,534,612	2026-03-31
Blackrock Inc.	11,222,407	2026-03-31
Suvretta Capital Management, LLC	10,286,937	2026-03-31
Stifel Financial Corporation	9,940,885	2026-03-31
State Street Corporation	6,618,803	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ABCL	$6.93	+6.13%	-5.91	$2.12B	0.00%
CLDX	$35.80	+0.63%	-7.84	$2.38B	0.00%
IMCRImmunocore Holdings plc	$31.95	-3.42%	-85.34	$1.62B	0.00%
IMNM	$23.22	+2.83%	-8.13	$2.22B	0.00%
NTLA	$10.89	+2.06%	-3.55	$1.22B	0.00%

About BHVN

BHVN is led by CEO Vladimir Coric, publicly traded since 2022.

BHVN stock trades at $14.07 with a market capitalization of $2.12B. The stock is valued at a price-to-earnings (P/E) ratio of -6.11, price-to-book of 13.87, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $7.48 and $18.57, and currently trades 24.2% below its 52-week high.

On profitability, BHVN generates a return on equity (ROE) of -333.00%, return on capital employed of -1432.69%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks NYSE High ROE Stocks All stock screens

Run Stock Screener Investing Guides